Seattle Genetics Inc $ 160.45 -1.35 (-0.83%)
Volume:
707,805
Avg Vol (1m):
1,108,488
Market Cap $:
27.92 Bil
Enterprise Value $:
27.09 Bil
P/E (TTM):
0.00
P/B:
15.38
Financial Strength | 7/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 14.07 | ||
| Equity-to-Asset | 0.84 | ||
| Debt-to-Equity | 0.04 | ||
| Debt-to-EBITDA | -0.22 | ||
| Piotroski F-Score | 5 | ||
| Altman Z-Score | 47.37 | ||
| Beneish M-Score | -2.38 | ||
| WACC vs ROIC | |||
Profitability Rank | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -32.94 | ||
| Net Margin % | -25.18 | ||
| ROE % | -15.03 | ||
| ROA % | -12.62 | ||
| ROC (Joel Greenblatt) % | -100.24 | ||
| 3-Year Revenue Growth Rate | 23.1 | ||
| 3-Year EBITDA Growth Rate | -8.4 | ||
| 3-Year EPS without NRI Growth Rate | 1.4 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 15.38 | ||
| PS Ratio | 27.1 | ||
| EV-to-EBIT | -80.97 | ||
| EV-to-EBITDA | -92.88 | ||
| EV-to-Revenue | 26.67 | ||
| Current Ratio | 4.71 | ||
| Quick Ratio | 4.39 | ||
| Days Inventory | 309.58 | ||
| Days Sales Outstanding | 104.25 | ||
| Days Payable | 215.27 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.5 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 22.41 | ||
| Price-to-Median-PS-Value | 1.5 | ||
| Earnings Yield (Greenblatt) % | -1.24 |